Back | Next |
home / stock / btai / btai message board
Subject | By | Source | When |
---|---|---|---|
BioXcel Therapeutics Appoints Michael P. Miller to Board | realfast95 | investorshub | 07/05/2022 11:51:21 AM |
Double bottom setup. $18.50 first target if it | frankyahoo | investorshub | 07/04/2022 6:18:08 PM |
nice chart | realfast95 | investorshub | 07/01/2022 8:32:53 PM |
blame H.C. Wainwright for Tuesday decline | realfast95 | investorshub | 05/25/2022 10:51:50 AM |
EMA Paediatric Investigation Plan modification approved this week | lettruthringout | investorshub | 05/20/2022 12:22:47 AM |
BioXcel's Igalmi: Potential Market For Acute Agitation In | realfast95 | investorshub | 05/18/2022 1:59:52 PM |
$BTAI CG Target $75. Predicts Alzh Dementia | realfast95 | investorshub | 05/13/2022 12:29:59 PM |
BioXcel Therapeutics price target lowered to $71 from | realfast95 | investorshub | 05/10/2022 12:31:31 PM |
Thanks for posting the transcript. | realfast95 | investorshub | 05/10/2022 11:31:57 AM |
Conference call transcript - pricing info | lettruthringout | investorshub | 05/10/2022 12:30:41 AM |
Guggenheim maintained $BTAI coverage with a Buy rating | realfast95 | investorshub | 05/09/2022 9:25:49 PM |
BioXcel Therapeutics Reports First Quarter 2022 Financial Results | realfast95 | investorshub | 05/09/2022 11:17:36 AM |
BioXcel Therapeutics reports Q1 EPS ($1.12), consensus ($1.15) | realfast95 | investorshub | 05/09/2022 11:12:49 AM |
Presentation Details: | realfast95 | investorshub | 05/05/2022 8:40:19 PM |
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY | realfast95 | investorshub | 05/03/2022 12:40:49 PM |
New journal publication | lettruthringout | investorshub | 04/29/2022 4:24:20 PM |
associated with projects that were ended | realfast95 | investorshub | 04/28/2022 3:51:24 PM |
article | realfast95 | investorshub | 04/28/2022 1:37:02 PM |
Earnings May 9th | realfast95 | investorshub | 04/27/2022 10:04:21 AM |
$BTAI Yesterday Canaccord Genuity reaffirmed their buy rating | realfast95 | investorshub | 04/26/2022 10:55:31 AM |
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...